Hemodialysis Market Size, Share, Outlook, Competitive Analysis and Forecast 2024-2031

Global Hemodialysis Market is segmented By Product Type (Peritoneal Dialysis Catheter, Chronic Haemodialysis Catheter, Acute Haemodialysis Catheter, Dialysis Machines, Hemodialysis Water Treatment Systems, Other), By Modality (Conventional Long-term Hemodialysis, In-Centre Hemodialysis, Home Haemodialysis), By End-User (Hospitals, Dialysis Centers, Homecare), and by Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Hemodialysis Market is expected to grow at a CAGR of 4.0% during the forecast period 2024-2031.

Hemodialysis is the process of purifying the blood of a person whose kidneys are not working normally. Hemodialysis functions are similar to an artificial kidney in patients with kidney failure and other renal impairments. Hemodialysis uses the artificial membrane to remove waste, such as urea, from the blood, restore the proper balance of electrolytes in the blood, and eliminate extra fluid from the body. Hemodialysis can be done in a hospital, in a dialysis center that is not part of a hospital, or at home.

Market Summary

For More Insights about the Market Request Free Sample

Market Dynamics

Hemodialysis market growth is driven by the increase in the incidence of hypertension and diabetes, a rise in the number of end-stage renal disorder patients, and a rise in the geriatric population.

The rise in the number of ESRD and the shortage in the availability of kidneys for transplant drives the market growth  

The rise in the number of ESRD and the shortage in the availability of kidneys for transplant is expected to drive the growth of the market. Chronic kidney disease (CKD) is a condition that causes reduced kidney function over some time. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become an enormous public health issue that continues to rise. For instance, as per a 2019 report by the Centers for Disease Control and Prevention, 15% of adults in the United States, which accounts for approximately 37 million people, are estimated to have CKD.

Additionally, as per the same source, CKD is more common among people aged 65 years or older (38%) than in people aged 45–64 years (13%) or 18–44 years (7%). Furthermore, it is more common in women (15%) than men (12%). Furthermore, high blood pressure (hypertension) and diabetes are the principal causes of kidney disease and kidney failure. In patients with diabetes, the small blood vessels in the body are injured and may cause damage to nerves resulting in improper blood purification by the kidneys and emptying bladder, further leading to kidney failure.

As per the World Health Organization, in 2019, an estimated 1.13 billion people, worldwide, had hypertension, with most patients (two-thirds) living in low- and middle-income countries. Moreover, hypertension is one of the major causes of premature death, worldwide. Additionally, As per the International Diabetes Federation (IDF) Diabetes Atlas Ninth edition 2019, it was found that globally approximately 463 million adults (20-79 years) were living with diabetes, and by 2045, it is expected to reach 700 million. Thus, owing to the rising burden of ESRD and the shortage in the availability of kidneys, there may be a huge demand for the hemodialysis market.

Risks and complications associated with dialysis will hamper the growth of the market

However, complications such as cardiac diseases and vascular access-related complications such as bleeding & infection, low blood pressure, nausea, hernia, hepatitis (B & C), and anemia are the major causes of mortality among dialysis patients. Peritonitis is a common complication of peritoneal dialysis resulting due to the contamination of peritoneal dialysate or tubing with pathogenic skin bacteria or catheter-related infections. These factors will hamper the growth of the market in the forecast period.

COVID-19 Impact on Market

The surge in the number of COVID cases, along with the rise in its severity rate, is likely to create a potential increase in the incidence of kidney damage. Due to the pandemic, the demand for renal replacement fluids has increased significantly worldwide. As per the American Society of Nephrology, in 2021,  the demand for RRT among patients with COVID-19 increased fivefold compared to the historical US population (4.9% as of 2020 VS. 0.9% earlier). The gradual shift towards home hemodialysis treatment before the pandemic and the concerns over the spread of COVID-19 infection have considerably accelerated patient interest in HD treatment. This factor is likely to drive the adoption of home hemodialysis products during the pandemic.

Market Segmentation Analysis

The conventional long-term hemodialysis segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)        

The conventional long-term hemodialysis treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using a hemodialysis machine as chosen by the responsible clinicians in hospitals. As per NCBI,  the relative mortality hazard for frequent versus conventional hemodialysis was 0.54 (95% confidence interval, 0.31 to 0.93).

According to the Organ Procurement and Transplantation Network, around 90,986 people as of February 2021 are waiting for kidney transplants in the United States. Thus, owing to the shortage of kidneys for transplant, the segment is expected to witness high growth. Furthermore, major manufacturers have focused on developing specialized dialysis equipment coupled with growing partnerships and collaboration among market players, which is expected to drive segment growth.

Market Geographical Share

The North American region holds the largest market share of the global hemodialysis market

The North American region is expected to dominate the hemodialysis market. This is majorly attributed due to better healthcare infrastructure and the presence of major market players. As per the Centers for disease control and prevention 2018, 15% of US adults, or 37 million people are estimated to have chronic kidney disease common in people aged 65 years or older (38%) than in people aged 45–64 years (13%) or 18–44 years.

Furthermore, as per the Chronic Kidney Disease in the United States, 2019 report, the number of people living with CKD in the United States was 37 million, and CKD is more common in women (15%) than men (12%). Moreover, according to the same report, CKD is one of the costliest disease conditions in the United States, which has been posing an economic burden of USD 83 billion, annually. Additionally, according to the Population Reference Bureau, the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060.

An aging population and a growing risk of chronic kidney disease are projected to significantly boost regional growth. Furthermore, manufacturers are focusing on developing specialized hemodialysis machines with different interventions. This is expected to impact the end-user experience. In addition, there is also an increase in public healthcare expenditure, coupled with the rising awareness programs, which is expected to drive the growth of the hemodialysis market in the North American region.

Companies and Competitive Landscape

The hemodialysis market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Asahi Kasei Corporation, B Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Cantel Medical Corp., DaVita Inc., Fresenius Medical Care AG & Co. KgaA, Medtronic PLC, Nipro Corporation, Rockwell Medical Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hemodialysis market globally. For instance, In December 2020, Medtronic launched its Carpediem Cardio-Renal Paediatric Dialysis Emergency Machine in the United States upon receiving Food and Drug Administration's (FDA) marketing authorization. The first machine was installed at Cincinnati Children's Hospital Medical Center.

B Braun Melsungen AG

Overview:

Braun Melsungen Aktiengesellschaft supplies healthcare products and services. The Company offers a product range for intensive care units, anesthesia, emergency care, extracorporeal blood treatments, and surgical core procedures.     

Product Portfolio:

Xevonta:  Xevonta allows for the efficient elimination of middle molecules and other uremic toxins while limiting the loss of serum albumin to 1.1±0.2g/ session. This is even the case with the largest 2.3m² surface-area dialyzers when used under post-dilution HDF conditions using high convective volumes.